The untapped potential of office-based buprenorphine treatment

JAMA Psychiatry

Volumn 72, Issue 4, 2015, Pages 395-396

  Sigmon, Stacey C ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NARCOTIC ANTAGONIST;

DRUG ABUSE; DRUG USE; HUMAN; LETTER; MEDICATION COMPLIANCE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT IDENTIFICATION; PATIENT MONITORING; PHYSICIAN; PRESCRIPTION DRUG DIVERSION; REIMBURSEMENT; SCREENING; UNITED STATES; AMBULATORY CARE; CLINICAL PRACTICE; OPIOID-RELATED DISORDERS; STATISTICS AND NUMERICAL DATA;

BUPRENORPHINE; HUMANS; NARCOTIC ANTAGONISTS; OFFICE VISITS; OPIOID-RELATED DISORDERS; PRACTICE PATTERNS, PHYSICIANS'; VERMONT;

EID: 84928346698     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.2421     Document Type: Letter

References (6)

1. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659
2. Birnbaum HG, White AG, SchillerM,Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657-667
3. Sigmon SC. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry. 2014;71(4):359-360
4. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies: tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22): 2063-2066
5. Substance Abuse and Mental Health Services Administration. Diversion and abuse of buprenorphine: a brief assessment of emerging indicators: results of the Vermont case study. 2006. http://buprenorphine.samhsa.gov/Vermont .Case.Study-12.5.06.pdf. Accessed June 27, 2014
6. Arfken CL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010;39(2): 96-104.